Media coverage about Icon (NASDAQ:ICLR) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Icon earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.9564164376975 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have effected Accern’s scoring:
- Icon (ICLR) Rating Increased to Hold at BidaskClub (americanbankingnews.com)
- Lazard Asset Management LLC Sells 14,597 Shares of Icon Plc (ICLR) (americanbankingnews.com)
- Alliancebernstein L.P. Acquires 24,571 Shares of Icon Plc (ICLR) (americanbankingnews.com)
- Icon Plc (ICLR) Position Reduced by UBS Asset Management Americas Inc. (americanbankingnews.com)
- Kennedy Capital Management Inc. Sells 17,021 Shares of Icon Plc (ICLR) (americanbankingnews.com)
ICLR has been the subject of a number of recent research reports. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $132.00 target price for the company in a research note on Tuesday, January 9th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Mizuho set a $109.00 target price on Icon and gave the company a “hold” rating in a research note on Wednesday, January 24th. KeyCorp reiterated an “overweight” rating and issued a $125.00 target price (up previously from $115.00) on shares of Icon in a research note on Monday, November 13th. They noted that the move was a valuation call. Finally, Evercore ISI initiated coverage on Icon in a research note on Thursday, January 18th. They issued an “outperform” rating and a $126.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $126.00.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.02. Icon had a return on equity of 27.55% and a net margin of 16.01%. The firm had revenue of $455.10 million during the quarter, compared to analyst estimates of $455.66 million. During the same quarter last year, the firm earned $1.33 EPS. Icon’s quarterly revenue was up 4.6% on a year-over-year basis. equities analysts anticipate that Icon will post 6.02 EPS for the current year.
WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3254222/icon-iclr-given-daily-coverage-optimism-score-of-0-13.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.